Alzheimer’s Drugs: Summary of Recommendations
- Full Report (296k PDF)
- 2-Page summary (96k PDF)
- Descargar El Resumen De 2 Páginas (261k PDF)
- Download Adobe Acrobat Reader
However, there is no way as yet to predict who will respond and who will get little or no benefit from one of the five drugs approved to treat Alzheimer's disease. Thus, the decision to try one is a gamble and judgment is based on whether the treatment is worth the cost and the risk of side effects.
- Cost. Averaging $148 to $195 a month, the Alzheimer's drugs are costly and may not be worth the added cost if the patient must take many other medicines. This is true even if insurance or Medicare coverage helps pay since out-of-pocket payments can still be quite steep.
- Side effects. While the long-term adverse effects of the Alzheimer's drugs have not been fully evaluated, short-term side effects are either mild or reversible when a person stops taking the medicine. On this basis, many people with Alzheimer's disease may opt to try one of the drugs for six months to a year to see if it helps. We advise close scrutiny of the patient's response by both family and physician.
- Donepezil (Aricept) — for people with early-stage Alzheimer's disease
- Galantamine (Razadyne) — for people with early-stage Alzheimer's disease
- Memantine (Namenda) — for people with middle-stage and late-stage Alzheimer's disease
Alzheimer’s Drugs: Drug Comparison
(1) As typically prescribed.
(2) Prices reflect nationwide retail average for January 2008, rounded to the nearest dollar (except where noted); information derived by Consumer Reports Best Buy Drugs from data provided by Wolters Kluwer Health, Pharmaceutical Audit Suite®."
(3) Brand name for galantamine has been changed from Reminyl to Razadyne in the U.S. to avoid name confusion with the diabetes drug Amaryl.
(2) Prices reflect nationwide retail average for January 2008, rounded to the nearest dollar (except where noted); information derived by Consumer Reports Best Buy Drugs from data provided by Wolters Kluwer Health, Pharmaceutical Audit Suite®."
(3) Brand name for galantamine has been changed from Reminyl to Razadyne in the U.S. to avoid name confusion with the diabetes drug Amaryl.
- Full Report (296k PDF)
- 2-Page summary (96k PDF)













